Physician profile
Charulatha P Nagar
NPI 1104810191
$111,620.15
in general payments reported to CMS, 2019-2025
13 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $8,412 · 2023: $26K · 2024: $39K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $22K · Travel and Lodging: $10K · Food and Beverage: $5,569 · Education: $55.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,225.00 |
| Consulting Fee | $21,940.00 |
| Travel and Lodging | $10,293.49 |
| Food and Beverage | $5,569.49 |
| Education | $55.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $107,317.38 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $2,282.41 | 2023-2025 | Rystiggo, Zilbrysq |
| Abbvie INC. | $1,294.53 | 2022-2024 | |
| W. L. Gore & Associates, INC. | $143.46 | 2024 | Gore Cardioform Septal Occluder |
| Biohaven Pharmaceuticals, INC. | $124.94 | 2021 | |
| Amneal Pharmaceuticals LLC | $119.91 | 2024 | Crexont |
| Genentech USA, INC. | $105.02 | 2023-2024 | Ocrevus, Enspryng |
| Alexion Pharmaceuticals, INC. | $90.47 | 2024-2025 | Soliris, Ultomiris |
| Janssen Biotech, INC. | $58.90 | 2025 | |
| Tg Therapeutics, INC. | $34.04 | 2025 | |
| Amgen INC. | $20.79 | 2024 | Uplizna |
| Kedrion Biopharma, INC. | $15.52 | 2024 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Pfizer INC. | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charulatha Nagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.